Clinical trial · Interventional
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites
NCT01327235CI-TRIAL-00015290completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Ascites | — | UNRESOLVED | — |
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Endostar | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Endostar
- interventionNames
- Drug: Endostar
- type
- ACTIVE_COMPARATOR
- label
- Cisplatin
- interventionNames
- Drug: Cisplatin
- type
- EXPERIMENTAL
- label
- Endostar and Cisplatin
- interventionNames
- Drug: Endostar
- Drug: Cisplatin
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of thoracic or abdominal tumor * At least medium amount of malignant pleural effusion or ascites * ECOG Performance Status 0-2 * Life expectancy ≥ 2 months * Adequate hematologic, cardiac, renal, and hepatic function * No major surgery within 4 weeks prior to this study * Written informed consent Exclusion Criteria: * Patients with central nervous system (CNS) metastases * Evidence of bleeding diathesis, serious infection * Evidence of myocardial infarction, unstable angina or cardiac insufficiency * Presence of serious COPD and/or respiratory failure * Allergic to study drug * Pregnant or lactating women * Participation in other clinical trials within 30 days prior to this study
References
Publications (0)
Data not yet available
No reference posted for this study.